Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
88.00    -0.50 (-0.56%)
Bid:
87.00
Ask:
89.00
Spread: 2.00 (2.299%)
Market Cap: £59.03m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

Regulatory Approval

2 Dec 2013 07:00

ECO Animal Health Group plc

(AIM: EAH)

2 December 2013

ECO RECEIVES FURTHER MARKETING AUTHORISATION FOR AIVLOSIN® IN RUSSIA

ECO is pleased to report that the Ministry of Agriculture of the Russian Federation has granted ECO a marketing authorisation for Aivlosin® 625 mg/g water soluble granules for drinking water medication for swine and poultry.

This very important authorisation comes a year after the first marketing authorisation in Russia for Aivlosin® 42.5 mg/g Premix for in-feed medication for swine. This new authorisation now allows for the servicing of both the poultry and pork producing industries and is a major expansion of ECO’s potential market.

Russia is the fourth largest poultry meat producer and seventh largest pork producing country. It has seen annual double-digit growth in pork and poultry meat production in the last 5 years driven by both domestic demand and import substitution, with accelerating adoption of large scale, intensive production techniques.

Aivlosin®, ECO’s patented macrolide antibiotic, is used for the medication of economical important respiratory and enteric (gut) diseases in pigs and poultry.

Peter Lawrence, Chairman of ECO, commented “This authorisation in Russia is most encouraging and is a further positive step in the development of Aivlosin® as a truly global, multi-species and versatile brand. It demonstrates ECO’s continued progress to being a major presence in the global market for animal health products.”

Contacts:

ECO Animal Health Group plc
Peter Lawrence 020 8336 6190
Spiro Financial
Anthony Spiro 020 8336 6196
Cenkos Securities plc (Nominated Adviser)
Stephen Keys 020 7397 8926

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Eco Animal Health Group Plc

Copyright Business Wire 2013

Date   Source Headline
23rd Nov 20227:00 amRNSResults for the six months ended 30 September 2022
22nd Nov 20227:00 amRNSInvestor Presentation covering Interim Results
14th Nov 20227:00 amRNSChange of Auditor
31st Oct 20227:00 amRNSBlock listing Interim Review
24th Oct 20221:30 pmRNSHolding(s) in Company
24th Oct 20221:28 pmRNSHolding(s) in Company
26th Sep 20224:01 pmRNSResult of AGM
5th Sep 20221:00 pmRNSInvestor Presentation covering Full Year Results
2nd Sep 20227:00 amRNSPublication of Annual Report and Notice of AGM
31st Aug 20227:00 amRNSFinal Results for the Year Ended 31 March 2022
26th Aug 20221:13 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHolding(s) in Company
22nd Aug 20227:00 amRNSRevised Notice of Results
9th Aug 20227:00 amRNSDirectorate Change
8th Aug 202211:05 amRNSSecond Price Monitoring Extn
8th Aug 202211:00 amRNSPrice Monitoring Extension
8th Aug 20227:00 amRNSNotice of Results and Trading Update
11th Jul 20227:00 amRNSNew Banking Facility
6th Jul 20227:00 amRNSPartnership with Moredun Research Institute
15th Jun 20227:35 amRNSPartnership with Imperial College
12th May 202212:05 pmRNSDirector/PDMR Dealings
29th Apr 202211:47 amRNSBlock Listing Interim Review
1st Apr 20227:00 amRNSDirector/PDMR Dealings
30th Mar 20227:00 amRNSDirector/PDMR Dealings
23rd Mar 20225:53 pmRNSDirector/PDMR Dealing
21st Mar 20227:00 amRNSDirector/PDMR Dealing
15th Mar 20227:00 amRNSPre-close Trading Update
23rd Feb 20227:00 amRNSNew Marketing Authorisations for Aivlosin in China
1st Feb 20221:53 pmRNSHolding(s) in Company
24th Jan 20227:00 amRNSInvestor Presentation
18th Jan 20227:01 amRNSHolding(s) in Company
18th Jan 20227:00 amRNSChief Executive Officer Appointment
13th Jan 20229:29 amRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update, Appointment of Joint Broker & CMD
6th Dec 20218:14 amRNSHolding(s) in Company
1st Dec 20217:00 amRNSBoard Appointment
30th Nov 202112:39 pmRNSDirector Dealings
25th Nov 20217:00 amRNSResults for the six months ended 30 September 2021
23rd Nov 20217:00 amRNSInvestor Presentation covering Interim Results
1st Oct 20218:47 amRNSTotal Voting Rights & Share Capital
27th Sep 202112:06 pmRNSDeferred Share Awards to Executive Directors
17th Sep 20217:00 amRNSResult of AGM
16th Sep 20217:00 amRNSAGM Statement
19th Aug 20217:00 amRNSPublication of Annual Report and Notice of AGM
12th Aug 20218:30 amRNSHolding(s) in Company
28th Jul 20212:40 pmRNSDirectors Dealings
26th Jul 20217:00 amRNSBoard Changes
26th Jul 20217:00 amRNSFinal Results for Year Ended 31 March 2021
28th May 20212:31 pmRNSTotal Voting Rights
12th May 20211:55 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.